Thomas Martin, MD, of the Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, reflects on studies investigating the use of BiTEs in relapsed/refractory myeloma treatment, a patient population with an unment need. Presented in ASCO 2020, Dr Martin highlights teclistamab, BCMA x CD3 bispecific antibody investigated in a Phase I dose-escalation study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).